[Form 4] Channel Therapeutics Corporation Insider Trading Activity
Insider Trade Summary
15,000 shares exercised/converted
Exercise
3 txns
Insider
LIGAND PHARMACEUTICALS INC
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Convertible Preferred Stock | 15,000 | $0.00 | $0.00 |
| Other | Series A Convertible Preferred Stock | 31,278.681 | $0.00 | $0.00 |
| Conversion | Common Stock | 1,500,000 | $10.00 | $15.00M |
Holdings After Transaction:
Series A Convertible Preferred Stock — 37,278.681 contracts (Direct);
Common Stock — 1,500,000 shares (Direct)
Footnotes (3)
- F1. The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.
- F2. Received in exchange for shares of LNHC, Inc. common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, Inc., a wholly-owned subsidiary of the reporting person, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, the reporting person.
- F3. The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
